F Stevenson

Summary

Affiliation: University of Southampton
Country: UK

Publications

  1. doi request reprint Follicular lymphoma and the immune system: from pathogenesis to antibody therapy
    Freda K Stevenson
    Molecular Immunology Group, Cancer Sciences Academic Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, United Kingdom
    Blood 119:3659-67. 2012
  2. ncbi request reprint Optimizing cancer immunotherapy trials: back to basics
    Freda K Stevenson
    Molecular Immunology Group, Cancer Sciences Division, Southampton University Hospitals Trust, Southampton, UK
    Eur J Immunol 36:1070-3. 2006
  3. ncbi request reprint Chronic lymphocytic leukemia: revelations from the B-cell receptor
    Freda K Stevenson
    Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals Trust, Southampton SO16 6YD, United Kingdom
    Blood 103:4389-95. 2004
  4. ncbi request reprint Update on cancer vaccines
    Freda K Stevenson
    Molecular Immunology Group, Cancer Sciences Division, Southampton University Hospitals Trust, UK
    Curr Opin Oncol 17:573-7. 2005
  5. ncbi request reprint Vaccine therapy in NHL: future promises and current limitations
    Freda K Stevenson
    Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals, Southampton, SO16 6YD, UK
    Leuk Lymphoma 44:S85-90. 2003
  6. ncbi request reprint DNA vaccines and adjuvants
    Freda K Stevenson
    Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals, Southampton, UK
    Immunol Rev 199:5-8. 2004
  7. ncbi request reprint DNA fusion gene vaccines against cancer: from the laboratory to the clinic
    Freda K Stevenson
    Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals, Southampton, UK
    Immunol Rev 199:156-80. 2004
  8. pmc DNA vaccines to attack cancer
    Freda K Stevenson
    Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals Trust, Southampton SO16 6YD, UK
    Proc Natl Acad Sci U S A 101:14646-52. 2004
  9. doi request reprint DNA vaccines against cancer come of age
    Freda K Stevenson
    Cancer Sciences Division, University of Southampton School of Medicine, Southampton General Hospital, Southampton, UK
    Curr Opin Immunol 22:264-70. 2010
  10. ncbi request reprint New strategies for vaccination and imunomodulation in NHL
    F K Stevenson
    Tenovus Laboratory, Southampton University Hospitals Trust, UK
    Ann Hematol 80:B132-4. 2001

Collaborators

Detail Information

Publications68

  1. doi request reprint Follicular lymphoma and the immune system: from pathogenesis to antibody therapy
    Freda K Stevenson
    Molecular Immunology Group, Cancer Sciences Academic Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, United Kingdom
    Blood 119:3659-67. 2012
    ..Clearly, mechanisms of attack vary with the malignancy, the target molecule, and the antibody design, offering opportunities for optimizing this promising strategy...
  2. ncbi request reprint Optimizing cancer immunotherapy trials: back to basics
    Freda K Stevenson
    Molecular Immunology Group, Cancer Sciences Division, Southampton University Hospitals Trust, Southampton, UK
    Eur J Immunol 36:1070-3. 2006
    ..These twin problems of engagement of T-cell help and delivery of adequate antigen can now be addressed by applying immunological logic to cancer vaccines...
  3. ncbi request reprint Chronic lymphocytic leukemia: revelations from the B-cell receptor
    Freda K Stevenson
    Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals Trust, Southampton SO16 6YD, United Kingdom
    Blood 103:4389-95. 2004
    ..Continuing regulatory activity, mediated via autoantigen, could suppress Ig production and lead to disease-associated hypogammaglobulinemia...
  4. ncbi request reprint Update on cancer vaccines
    Freda K Stevenson
    Molecular Immunology Group, Cancer Sciences Division, Southampton University Hospitals Trust, UK
    Curr Opin Oncol 17:573-7. 2005
    ..We also have modern assays using surrogate markers of performance to correlate with clinical effects. It is timely to select significant relevant papers to illustrate the growing potential for patients with cancer...
  5. ncbi request reprint Vaccine therapy in NHL: future promises and current limitations
    Freda K Stevenson
    Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals, Southampton, SO16 6YD, UK
    Leuk Lymphoma 44:S85-90. 2003
    ..This induces fast cytotoxic T-cell attack on peptide-expressing tumor cells. Injection of DNA appears safe and clinical trials will test the efficacy of this approach, and probably lead to improvements in these flexible vaccines...
  6. ncbi request reprint DNA vaccines and adjuvants
    Freda K Stevenson
    Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals, Southampton, UK
    Immunol Rev 199:5-8. 2004
  7. ncbi request reprint DNA fusion gene vaccines against cancer: from the laboratory to the clinic
    Freda K Stevenson
    Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals, Southampton, UK
    Immunol Rev 199:156-80. 2004
    ..Vaccination strategies against cancer and against microbes are sharing knowledge and technology for mutual benefit...
  8. pmc DNA vaccines to attack cancer
    Freda K Stevenson
    Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals Trust, Southampton SO16 6YD, UK
    Proc Natl Acad Sci U S A 101:14646-52. 2004
    ..Physical methods including electroporation provide increased expression without introducing additional competing antigens. A wide range of cancers can be targeted, and objective assays of response will determine efficacy...
  9. doi request reprint DNA vaccines against cancer come of age
    Freda K Stevenson
    Cancer Sciences Division, University of Southampton School of Medicine, Southampton General Hospital, Southampton, UK
    Curr Opin Immunol 22:264-70. 2010
    ..Prolongation of remission is the goal and an activated immune system should achieve this...
  10. ncbi request reprint New strategies for vaccination and imunomodulation in NHL
    F K Stevenson
    Tenovus Laboratory, Southampton University Hospitals Trust, UK
    Ann Hematol 80:B132-4. 2001
    ..There is no evidence so far of toxicity due to injection of DNA, but for antigens which are expressed by normal cells, the line between attack on tumour and autoimmunity will have to be carefully drawn...
  11. ncbi request reprint Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes
    F Stevenson
    Tenovus Laboratory, Southampton University Hospitals Trust, UK
    Immunol Rev 162:247-59. 1998
    ..It also has a clear clinical relevance in tracking tumor cells, measuring residual disease, and finally in offering the opportunity of developing vaccines for treatment...
  12. ncbi request reprint DNA vaccines against haematological malignancies
    F K Stevenson
    Tenovus Laboratory, Southampton University Hospitals Trust, UK
    Haematologica 84:11-3. 1999
    ..The critical clinical requirement, however, will be to treat the presenting tumour with maintenance or restoration of immune capacity. We await results of the preliminary clinical trials with great interest...
  13. doi request reprint DNA fusion vaccines enter the clinic
    Freda K Stevenson
    Molecular Immunology Group, Cancer Sciences Division, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
    Cancer Immunol Immunother 60:1147-51. 2011
    ..Clinical trials of patients with cancer are showing induction of responses, with preliminary indications of suppression of tumor growth and evidence for clinically manageable concomitant autoimmunity...
  14. ncbi request reprint DNA vaccination: a potential weapon against infection and cancer
    F K Stevenson
    Molecular Immunology Group, Tenovus Laboratory and Division of Cell and Molecular Medicine, Southampton University Hospitals Trust, Southampton SO16 6YD, UK
    Vox Sang 80:12-8. 2001
    ..The ease of manipulation of gene sequences, together with the increasing knowledge of the operation of the immune system, means that we now have the tools to take vaccines into the next exciting stage of development...
  15. ncbi request reprint Immunotherapy for multiple myeloma: insights from other models
    F K Stevenson
    Tenovus Research Laboratory, Department of Molecular Immunology, Southampton General Hospital, UK
    Leuk Res 26:403-5. 2002
  16. doi request reprint B-cell receptor signaling in chronic lymphocytic leukemia
    Freda K Stevenson
    Molecular Immunology Group, Cancer Sciences, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, United Kingdom
    Blood 118:4313-20. 2011
    ..New inhibitors of BCR signaling appear to have clinical activity. In this Perspective, we discuss the functional significance of the BCR in CLL, and we describe strategies to target BCR signaling as an emerging therapeutic approach...
  17. ncbi request reprint The immunoglobulin VH gene, VH4-21, specifically encodes autoanti-red cell antibodies against the I or i antigens
    G Smith
    Wessex Blood Transfusion Centre, Tenovus Laboratory, Southampton, UK
    Vox Sang 68:231-5. 1995
    ..The 9G4 antibody therefore provides a simple tool for discrimination between these autoanti-red cell antibodies, which should be of use in red cell serology...
  18. pmc Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help
    Natalia Savelyeva
    Molecular Immunology Group, Cancer Sciences Division, Southampton University Hospitals Trust, Southampton, Hampshire SO16 6YD, United Kingdom
    Proc Natl Acad Sci U S A 102:10987-92. 2005
    ..The principles revealed by using a DNA vaccine have implications for all cancer vaccines designed to induce and maintain antibody responses against weak autologous tumor antigens...
  19. ncbi request reprint Failure of vaccination with idiotypic protein or DNA, (+/-IL-2), the depletion of regulatory T cells, or the blockade of CTLA-4 to prolong dormancy in mice with BCL1 lymphoma
    Laurentiu M Pop
    Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas, Texas 75390 8576, USA, and Cancer Sciences Division, Southampton University Hospitals, UK
    J Immunother 28:525-34. 2005
    ..They also suggest that the elimination of dormant tumor may represent a greater challenge than the elimination of primary tumors...
  20. ncbi request reprint Vaccination of human subjects expands both specific and bystander memory T cells but antibody production remains vaccine specific
    Gianfranco Di Genova
    Molecular Immunology Group, Cancer Sciences Division, Southampton University Hospitals Trust, Southampton, Hampshire SO16 6YD, United Kingdom
    Blood 107:2806-13. 2006
    ..These findings relate to the maintenance of memory and have consequences for assessments of specific T-cell responses to vaccination...
  21. ncbi request reprint Idiotype gene rescue in follicular lymphoma
    Katy McCann
    Cancer Sciences Division, Southampton University Hospitals, UK
    Methods Mol Med 115:145-71. 2005
    ..In this chapter, we focus on the analysis of V genes in follicular lymphomas based on the experience in our laboratory and provide a detailed guide for this analysis...
  22. ncbi request reprint Determining mutational status of immunoglobulin v genes in chronic lymphocytic leukemia: a useful prognostic indicator
    Surinder S Sahota
    Cancer Sciences Division, Southampton University Hospitals NHS Trust, University of Southampton, UK
    Methods Mol Med 115:129-44. 2005
    ..This chapter describes in detail the methodology for determining V gene usage in CLL, from acquisition of patient sample to generating the V-gene readout...
  23. ncbi request reprint Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia
    Kathleen N Potter
    Molecular Immunology Group, Tenovus Research Laboratory, Cancer Sciences Division, Southampton General Hospital, Southampton, UK
    Clin Cancer Res 12:1672-9. 2006
    ....
  24. ncbi request reprint Identification and assembly of V genes as idiotype-specific DNA fusion vaccines in multiple myeloma
    Surinder S Sahota
    Molecualr Immunology Group, Tenovus Laboratory, Southampton University Hospitals, Southampton, UK
    Methods Mol Med 113:105-19. 2005
    ..These scFv.FrC DNA vaccines provide protection in myeloma models and are currently in clinical trials. The vaccines are patient specific and can be rapidly assembled for clinical use...
  25. ncbi request reprint DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens
    Jason Rice
    Molecular Immunology Group, Southampton University Hospitals Trust, Southampton, Hampshire, United Kingdom
    Cancer Res 66:5436-42. 2006
    ..These safe epitope-specific vaccines offer a potential strategy to prime HA-1- or HA-2-specific CTL in transplant donors before adoptive transfer...
  26. pmc DNA fusion gene vaccination mobilizes effective anti-leukemic cytotoxic T lymphocytes from a tolerized repertoire
    Jason Rice
    Molecular Immunology Group, Cancer Sciences Division, University of Southampton School of Medicine, Southampton, UK
    Eur J Immunol 38:2118-30. 2008
    ..These results demonstrate a simple strategy to engage anti-microbial T cell help to activate epitope-specific polyclonal CD8(+) T cell responses from a residual tolerized repertoire...
  27. doi request reprint DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance
    Coralie Chaise
    INSERM U 841, Institut Mondor de Recherche Biomédicale IMRB, Departement d Immunologie, Dermatologie et Oncologie, Creteil, France
    Blood 112:2956-64. 2008
    ....
  28. doi request reprint DNA vaccines: precision tools for activating effective immunity against cancer
    Jason Rice
    Genetic Vaccine Group, Cancer Sciences Division, University of Southampton School of Medicine, Southampton General Hospital, Southampton, SO16 6YD, UK
    Nat Rev Cancer 8:108-20. 2008
    ..Recently, novel delivery systems, especially electroporation, have overcome this translational block. Here, we assess the development, current performance and potential of DNA vaccines for the treatment of cancer...
  29. doi request reprint Tapasin shapes immunodominance hierarchies according to the kinetic stability of peptide-MHC class I complexes
    Stephen M Thirdborough
    Cancer Sciences Division, University of Southampton School of Medicine, SGH, Southampton, UK
    Eur J Immunol 38:364-9. 2008
    ..Our findings reveal strategies for activating T cells against low-affinity peptides, of potential importance for patients with repertoires narrowed by deletional tolerance...
  30. ncbi request reprint Public T cell receptor beta-chains are not advantaged during positive selection
    Anna L Furmanski
    Department of Immunology, Hammersmith Hospital, Imperial College London, London, United Kingdom
    J Immunol 180:1029-39. 2008
    ..Therefore, the establishment and maintenance of public beta-chains in the periphery is predominantly controlled by post-thymic events through modification of the primary, thymus-derived TCR repertoire...
  31. ncbi request reprint Prolonged antigen expression following DNA vaccination impairs effector CD8+ T cell function and memory development
    Joanna N Radcliffe
    Cancer Sciences Division, University of Southampton School of Medicine, Southampton General Hospital, Southampton, United Kingdom
    J Immunol 179:8313-21. 2007
    ..Transient expression at priming therefore led to a net higher secondary response. In terms of vaccine design, we propose that the most effective DNA-based CD8+ T cell vaccines will be those that deliver a short burst of Ag...
  32. ncbi request reprint Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma
    Katy J McCann
    Genetic Vaccine Group, Cancer Sciences Division, University of Southampton School of Medicine, Southampton, UK
    Mol Immunol 45:1567-72. 2008
    ..The remarkable selective glycosylation within the heavy chain V region gene of FL apparently permits only limited processing to oligomannose at somatically mutated motifs, creating a feature exploitable by GC lymphomas...
  33. pmc A DNA fusion vaccine induces bactericidal antibodies to a peptide epitope from the PorA porin of Neisseria meningitidis
    Delin Zhu
    Genetic Vaccine Group, Cancer Sciences Division, University of Southampton Medical School, Southampton General Hospital, Southampton SO16 6YD, United Kingdom
    Infect Immun 76:334-8. 2008
    ..These data provide proof of principle for a DNA fusion plasmid strategy as a novel approach to preparing vaccines based on defined, protective epitopes...
  34. ncbi request reprint Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status
    C Ian Mockridge
    Molecular Immunology Group, Tenovus Laboratory, University of Southampton, Southampton General Hospital, Southampton, United Kingdom
    Blood 109:4424-31. 2007
    ..Downstream signaling pathways, therefore, appear intact in CLL, locating anergy to sIgM, mainly in M-CLL. Integration of differential isotype-specific effects mediated by (auto)antigen may determine tumor behavior...
  35. ncbi request reprint Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor
    Catherine M Radcliffe
    Glycobiology Institute, Medical Research Council Immunochemistry Unit, Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, United Kingdom
    J Biol Chem 282:7405-15. 2007
    ..These findings suggest a potential contribution to lymphoma pathogenesis involving antigen-independent interaction of surface immunoglobulin of the B-cell receptor with mannose-binding molecules of innate immunity in the germinal center...
  36. ncbi request reprint PASD1 is a potential multiple myeloma-associated antigen
    Surinder S Sahota
    Blood 108:3953-5. 2006
  37. ncbi request reprint Prime-boost with alternating DNA vaccines designed to engage different antigen presentation pathways generates high frequencies of peptide-specific CD8+ T cells
    Joanna N Radcliffe
    Cancer Sciences, University of Southampton School of Medicine, Southampton General Hospital, Southampton, United Kingdom
    J Immunol 177:6626-33. 2006
    ..Taken together, these results demonstrate that vaccination protocols involving different modes of Ag presentation at prime and boost can significantly improve the effectiveness of immunization...
  38. ncbi request reprint Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen
    Sarah Buchan
    Molecular Immunology Group, Southampton University Hospitals Trust, Southampton, United Kingdom
    J Immunol 174:6292-8. 2005
    ..Therefore, boosting may not require viral vectors, but simply a physical change in delivery, facilitating application to the cancer clinic...
  39. pmc Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia
    Graham Packham
    Cancer Research UK Oncology Unit, University of Southampton School of Medicine, Southampton General Hospital, Southampton, UK
    Immunology 114:441-9. 2005
    ..The differential properties of the newly described subsets of CLL are also highlighted...
  40. ncbi request reprint Origins of the malignant clone in typical Waldenstrom's macroglobulinemia
    Surinder S Sahota
    Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals, UK
    Semin Oncol 30:136-41. 2003
    ..In contrast, IgM-secreting multiple myeloma arises at a later stage in differentiation, when isotype switch mechanisms have been engaged...
  41. ncbi request reprint Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma
    Delin Zhu
    Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals, UK
    Br J Haematol 120:217-22. 2003
    ..Patients with MALT lymphoma had a low frequency (9%) of novel sites, comparable to normal B cells. These findings distinguish glycosylation sites from ongoing mutation and may reflect different environmental influences on these tumours...
  42. ncbi request reprint Features of the overexpressed V1-69 genes in the unmutated subset of chronic lymphocytic leukemia are distinct from those in the healthy elderly repertoire
    Kathleen N Potter
    Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals Trust, Southampton, United Kingdom
    Blood 101:3082-4. 2003
    ..These findings support the concept that CLL arises from B cells driven by antigen/superantigen and is not a stochastic event in the elderly B-cell population...
  43. ncbi request reprint A gamma-herpesvirus immune evasion gene allows tumor cells in vivo to escape attack by cytotoxic T cells specific for a tumor epitope
    Jason Rice
    Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals Trust, Southampton, GB
    Eur J Immunol 32:3481-7. 2002
    ..They may have relevance for escape of human virus-associated malignancies, and raise the question of whether analogous molecules might contribute to the failure of CTL to eliminate tumors...
  44. ncbi request reprint Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen
    Jason Rice
    Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals Trust, Southampton, United Kingdom
    J Immunol 169:3908-13. 2002
    ..These data demonstrate the power of epitope-specific CTL against tumor cells and illustrate a strategy for priming immunity via a dual component DNA vaccine...
  45. ncbi request reprint Evidence for involvement of a hydrophobic patch in framework region 1 of human V4-34-encoded Igs in recognition of the red blood cell I antigen
    Kathleen N Potter
    Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals Trust, Southampton, United Kingdom
    J Immunol 169:3777-82. 2002
    ..This interaction could leave most of the conventional binding site available for binding other Ags...
  46. pmc Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses
    Francesco Forconi
    Cattedra e U O di Ematologia, Ospedale A Sclavo, Universita di Siena, Italy
    Immunology 107:39-45. 2002
    ..The findings underpin the approach of DNA idiotypic fusion vaccination for patients with B-cell tumours...
  47. ncbi request reprint Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events
    Surinder S Sahota
    Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals, Southampton, United Kingdom
    Blood 100:1505-7. 2002
    ..These data support the concept that typical WM is derived from a B cell that has undergone somatic mutation prior to transformation, at a point where isotype switch events have not been initiated. (Blood. 2002;100:1505-1507)..
  48. ncbi request reprint Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma
    Stephen M Thirdborough
    Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals Trust, Southampton SO16 6YD, United Kingdom
    Cancer Res 62:1757-60. 2002
    ..This is the first report of a DNA vaccine able to induce anti-idiotypic immunity against TCL, and it presents a simple strategy for selectively eliminating T-cell clones in vivo...
  49. ncbi request reprint Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma
    Delin Zhu
    Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals Trust, Southampton SO16 6YD, United Kingdom
    Blood 99:2562-8. 2002
    ..One possibility is that the added carbohydrate in the variable region contributes to interaction with elements in the germinal center environment. This common feature of FL may be critical for tumor behavior...
  50. ncbi request reprint DNA gene fusion vaccines against cancer
    Delin Zhu
    Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals Trust, UK
    Curr Opin Mol Ther 4:41-8. 2002
    ..These strategies are particularly important for cancer vaccines to increase their immunogenicity and to overcome tolerance...
  51. ncbi request reprint Mantle cell lymphoma with t(11;14) and unmutated or mutated VH genes expresses AID and undergoes isotype switch events
    Gavin Babbage
    Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals, UK
    Blood 103:2795-8. 2004
    ..UM MCLs implicate origins from pre-GC B cells and reveal switch events at ectopic sites...
  52. ncbi request reprint Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch
    Francesco Forconi
    Unità Operativa Complessa Ematologia e Trapianti, Dipartimento di Medicina Clinica e Scienze Immunologiche, Universita di Siena, Italy
    Blood 104:3312-7. 2004
    ..Both mutational and switching events may be influenced by environmental factors at extrafollicular sites...
  53. ncbi request reprint DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire
    Jason Rice
    Molecular Immunology Group, Southampton University Hospitals Trust, Southampton, Hampshire, United Kingdom
    J Immunol 173:4492-9. 2004
    ..For patients, vaccination could activate a potentially less tolerized repertoire against similar Ags that may be overexpressed by tumor cells, for focused immune attack...
  54. ncbi request reprint Engineering DNA vaccines that include plant virus coat proteins
    Natalia Savelyeva
    Molecular Immunology Group, Cancer Sciences Division, Southampton University Hospitals Trust, Tremona Road, Southampton, SO16 6YD, UK
    Biotechnol Genet Eng Rev 20:101-14. 2003
  55. ncbi request reprint Tumor vaccines
    Freda K Stevenson
    Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division Southampton University Hospitals Trust, Southampton SO16 6YD, United Kingdom
    Adv Immunol 82:49-103. 2004
  56. ncbi request reprint Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency
    Francesco Forconi
    Divisione di Ematologia e Trapianti, Dipartimento di Medicina Clinica e Scienze Immunologiche Applicate, Universita di Siena, Siena, Italy
    Br J Haematol 124:604-9. 2004
    ....
  57. ncbi request reprint Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt-like" lymphomas from naive B cells
    Delin Zhu
    Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals Trust, Southampton SO16 6YD, United Kingdom
    Blood 105:2135-7. 2005
    ..In contrast, human eBL development occurs in a GC or post-GC site with a likely contribution to pathogenesis from Epstein-Barr virus (EBV) and other epigenetic factors...
  58. ncbi request reprint VP22 enhances antibody responses from DNA vaccines but not by intercellular spread
    Stuart D Perkins
    Biomedical Sciences Department, Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire SP4 OJQ, UK
    Vaccine 23:1931-40. 2005
    ..These data suggest that amplification of the immune response may occur via mechanisms other than VP22-mediated intercellular spread of antigen...
  59. ncbi request reprint Anti-idiotype vaccines
    Helen McCarthy
    Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals Trust, Southampton, UK
    Br J Haematol 123:770-81. 2003
  60. ncbi request reprint CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease
    Terry J Hamblin
    Department of Haematology, Royal Bournemouth Hospital, Castle Lane East, Bournemouth, BH7 7DW, United Kingdom
    Blood 99:1023-9. 2002
    ..Additional prospective studies are required for comparing CD38 expression with other prognostic factors and for taking sequential measurements during the course of the disease...
  61. ncbi request reprint Proteomic analysis of chronic lymphocytic leukemia subtypes with mutated or unmutated Ig V(H) genes
    Duncan A E Cochran
    Leukaemia Research Fund Proteomics Facility, Department of Biomolecular Sciences, University of Manchester Institute of Science and Technology, United Kingdom
    Mol Cell Proteomics 2:1331-41. 2003
    ..The results presented show that proteomic analysis can complement other approaches in identifying proteins that may have potential value in the biological and diagnostic distinction between important clinical subtypes of CLL...
  62. ncbi request reprint The relevance of sequence insertions in the Mcl-1 promoter in chronic lymphocytic leukemia and in normal cells
    Silvia Coenen
    Haematologica 90:1285-6. 2005
    ..Thus, Mcl-1 insertions are not acquired during leukemogenesis and are unlikely to play an important role in this disease...
  63. ncbi request reprint V(H) gene analysis of splenic marginal zone lymphomas reveals diversity in mutational status and initiation of somatic mutation in vivo
    Delin Zhu
    Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals, United Kingdom
    Blood 100:2659-61. 2002
    ..Importantly, because several replacement mutations were located within or close to the complementarity-determining regions (CDRs), it raises the question of a role for antigen in driving tumor growth...
  64. ncbi request reprint Common patterns of B cell perturbation and expanded V4-34 immunoglobulin gene usage in autoimmunity and infection
    C Ian Mockridge
    Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals Trust, Tremona Road, Southampton SO16 6YD, UK
    Autoimmunity 37:9-15. 2004
    ..If so, censoring is bypassed following EBV infection, after which equilibrium is restored. Continuing high serum levels in SLE may arise either by disordered regulation, or by subclinical reactivation of endogenous virus...
  65. ncbi request reprint Patterns of somatic mutations in VH genes reveal pathways of clonal transformation from MGUS to multiple myeloma
    Niklas Zojer
    Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals, Southampton, United Kingdom
    Blood 101:4137-9. 2003
    ..Transformation can occur at either MGUS stage, but it involves a single cell in which somatic mutation is then silent...
  66. ncbi request reprint Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines
    Gavin Babbage
    Genetic Vaccine Group and Cancer Sciences Division, School of Medicine, University of Southampton, Southampton, United Kingdom
    Cancer Res 66:3996-4000. 2006
    ..Constitutive AID activation in malignant epithelial cells further raises a potential for inducing aberrant mutational activity...
  67. ncbi request reprint Intronic BCL-6 mutations are preferentially targeted to the translocated allele in t(3;14)(q27;q32) non-Hodgkin B-cell lymphoma
    Fabrice Jardin
    Department of Haematology, Centre Henri Becquerel, 76000 Rouen, France
    Blood 102:1872-6. 2003
    ..Junctional sequences indicate translocation origins from earlier BCL-6 mutations and switch recombinase events...
  68. ncbi request reprint Lineage complexity in multiple myeloma?
    Surinder Singh Sahota
    Leuk Lymphoma 47:1997-8. 2006